Issued 1,000,000 new shares under the 4th third-party allotment at 373 yen per share, raising a total of 373,000,000 yen. Issued 10,500 stock acquisition rights with issuance proceeds of 598,374,000 yen; potential shares total 1,050,000 shares. Allottee: CVI Investments, Inc. Publication of payment completion date and allotment terms.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4888","jir_company_name":"Stella Pharma Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4888-20261104-01.pdf","jir_short_summary":"Issued 1,000,000 new shares under the 4th third-party allotment at 373 yen per share, raising a total of 373,000,000 yen. Issued 10,500 stock acquisition rights with issuance proceeds of 598,374,000 yen; potential shares total 1,050,000 shares. Allottee: CVI Investments, Inc. Publication of payment completion date and allotment terms.","jir_summary":"### Overview of Capital Policy Implementation\nStella Pharma Corporation will issue 1,000,000 new shares to CVI Investments, Inc., an investment vehicle managed by a U.S. institutional investor, as the 4th third-party allotment at 373 yen per share, raising a total of 373,000,000 yen. Concurrently, the company will issue 10,500 stock acquisition rights, bringing the total potential shares to 1,050,000 shares. The issuance price of the stock acquisition rights is 288 yen per right, the exercise price is 567 yen, and the exercise period is from November 5, 2026 to November 4, 2030. The allottee is CVI Investments, Inc.\n\n### Impact on Shareholders and Future Outlook\nThrough this third-party allotment and issuance of stock acquisition rights, the company aims to strengthen its capital base for the future. While the increase in issued shares and expansion of potential shares may result in dilution, the impact on investors could be limited depending on the purposes of the fundraising and the planned use of proceeds. The allottee is expected to be engaged in a long-term relationship, and this capital policy is intended to enhance the company\u2019s market fundraising capability. Attention will be focused on future procedural developments and the progress of exercise activity.","jir_financial_highlights":"Number of common shares issued: 1,000,000 shares (Unknown)\nIssue price: 373 yen (Unknown)\nAmount of funds raised: 373,000,000 yen (Unknown)\nTotal number of stock acquisition rights: 10,500 cases (Unknown)\nIssue price (per stock acquisition right): 288 yen (Unknown)\nPotential number of shares: 1,050,000 shares (Unknown)\nAmount of fundraising (stock acquisition rights issuance + upon exercise): 598,374,000 yen (Unknown)\nExercise price: 567 yen (Unknown)\nExercise request period: From November 5, 2026 to November 4, 2030 (Unknown)","jir_category":"","jir_hashtags":"#StellaPharma, #CapitalPolicyImplementation, #ThirdPartyAllotment","jir_key_figures":"Number of common shares issued: 1,000,000 shares\nIssue price: 373 yen\nAmount of funds raised: 373,000,000 yen","jir_meta_title":"Stella Pharma Corporation: Completion of Payment for 4th Third-Party Allotment of New Shares and Stock Acquisition Rights | November 4, 2026","jir_meta_description":"Stella Pharma Corporation issued 1,000,000 new shares at 373 yen each through its 4th third-party allotment, raising 373,000,000 yen. Issued 10,500 stock acquisition rights; exercise period November 5, 2026\u2013November 4, 2030. Allottee: CVI Investments, Inc.","jir_og_title":"Stella Pharma Corporation: Completion of Payment for 4th Third-Party Allotment of New Shares and Stock Acquisition Rights","jir_og_description":"Stella Pharma Corporation issued 1,000,000 new shares at 373 yen under the 4th third-party allotment, raising 373,000,000 yen. Stock acquisition rights were also issued. Allottee: CVI Investments, Inc.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59263,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-141158","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n